CCH Health NetNews
Home  |  Products  |  Health Law Blog  |  Contact Us November 1, 2013 Edition


Note to readers:

Our subscribers told us that they are challenged by the high volume of information they need to process. They stated it’s not the quantity of information that’s important, it’s getting the right high-value information at the right time. To meet the goal of providing valuable resources while reducing email load, we have updated and consolidated our Health Net News emails into a single source of professional health care information and solutions. Covering content in Health Care Compliance, Medicare and Medicaid Reimbursement, Health Reform, and Life Sciences, this resource is designed to provide you with the content and features most useful to you, highlighting the key developments of the month.


Perampanel proposed as Schedule III controlled substance

The Drug Enforcement Administration (DEA) is proposing to place the substance perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl) benzonitrile hydrate], including its salts, isomers, and salts of isomers, into Schedule III of the Controlled Substances Act (CSA).

If finalized, this Proposed rule would impose regulatory controls and administrative, civil, and criminal sanctions of Schedule III controlled substances on individuals who handle (manufacture, distribute, dispense, import, export, engage in research, conduct instructional activities, and possess) or even propose to handle perampanel. This Proposed rule is based on a recommendation from the Assistant Secretary for HHS and on an evaluation of all other relevant data by the DEA. Comments on the proposal should be submitted no later than November 21, 2013. FDA Proposal, ¶46,211

Read IntelliConnect »  |  Not a Subscriber?

Back to Top

FDA proposes changes for annual report on data collected from sponsors of antimicrobial new animal drugs

The FDA has issued a proposed rule regarding the content and format of data tables for its annual summary report of sales and distribution data collected from sponsors of antimicrobial new animal drugs, in accordance with the new animal drug records and reporting provisions of the Federal Food, Drug, and Cosmetic Act (FDCA). Comments on the proposed rule are due November 23, 2013. FDA Proposal, ¶46,210

Read IntelliConnect »  |  Not a Subscriber?

Back to Top

FDA request to delay issuance of proposed food safety regulations refused

The FDA is required submit a notice of proposed rulemaking (NPRM) regarding intentional adulteration rules by the court-ordered November 30, 2013 deadline. Although the FDA requested a stay pending the appeal of the court’s order, there was no reason to grant it, because the court determined that submitting the NPRM was unlikely to cause irreparable harm to the FDA. Center for Food Safety v Hamburg, N.D. Cal., ¶39,462

Read IntelliConnect »  |  Not a Subscriber?

Back to Top

State failure to warn claims against generic drug manufacturer preempted

Pro se products liability claims brought against a generic drug manufacturer based on a failure-to-warn theory were preempted by federal law. Because the generic drug manufacturer was required to use the same FDA approved labeling as the brand manufacturer, and could not legally change the labeling even to add additional warnings, the state law claims alleging that the labeling was inadequate would conflict with FDA regulations and were therefore preempted. Ko v Mutual Pharmaceutical Company, Inc., N.D. Cal., ¶39,461

Read IntelliConnect »  |  Not a Subscriber?

Back to Top

You are subscribed to NetNews, sponsored by Wolters Kluwer Law & Business. Click here to unsubscribe. To manage your newsletter preferences or subscribe, click here.

To unsubscribe via postal mail, please contact us at: Wolters Kluwer Law & Business, Attn: Business Compliance Marketing, 2700 Lake Cook Rd., Riverwoods, IL 60015. Please include the email address you have been contacted with.

© CCH, Incorporated. All Rights Reserved.

Quick Links

  • Headlines
  • Featured Products

    Health Reform Toolkit

    A suite of electronic Smartcharts that help you gain quick knowledge on how these laws impact your organization by breaking down the 3000 plus pages of legislation into easy to understand topics related to the hospital, pharmaceutical, and legal industries.

    Learn More »

    Medicare and Medicaid Guide

    Your exclusive source for all Medicare and Medicaid information, with emphasis on the critical issue of payment. Offers comprehensive, full-text reporting of federal Medicare and Medicaid law and regulation provisions and summary reporting of state.

    Learn More »

    About this Newsletter

    To access IntelliConnect full text documents you must be a subscriber to the Food, Drug and Cosmetic Law
    , IntelliConnect product (depending on the link).*

    Links within news stories display full text documents including legislation, regulations, court decisions, rulings and government reports.

    The first time you click on a link you will be taken to the standard IntelliConnect login page, where you will need to enter your ID and password. Subsequent links will take you directly to the desired document.

    Sign up for NetNews

    Receive the NetNews newsletters via e-mail and to stay up-to-date on all the latest developments.

    Subscribe Now

    Privacy Policy